Search

Your search keyword '"Crugnola, Monica"' showing total 240 results
Start Over Author "Crugnola, Monica" Language english
240 results on '"Crugnola, Monica"'

1. Transfusion independence after lenalidomide discontinuation in patients with del(5q) myelodysplastic neoplasm: a HARMONY Alliance study

Author

Crisà, Elena, Mora, Elvira, Germing, Ulrich, Bally, Cecile, Diez Campelo, Maria, Myllymäki, Mikko, Jädersten, Martin, Komrokji, Rami, Platzbecker, Uwe, Haase, Detlef, Hofmann, Wolf-Karsten, Al Ali, Najla H., Barraco, Daniela, Bargay, Juan José, Bernal, Teresa, López Cadenas, Felix, Calvisi, Anna, Capodanno, Isabella, Cerrano, Marco, Ciancia, Rosanna, Crugnola, Monica, Kündgen, Andrea, Finelli, Carlo, Fozza, Claudio, Frairia, Chiara, Freja, Ebeling, Ganster, Christina, Kubasch, Anne Sophie, Jimenez, Maria Jose, Latagliata, Roberto, Hernandez Mohedo, Francisca, Molero, Antonieta, Vara Pampliega, Miriam, Perez, Clara Aparicio, Pietrantuono, Giuseppe, Poloni, Antonella, Pomares, Helena, Recasens, Valle, Rüfer, Axel, Signori, Alessio, Hellstrom-Lindberg, Eva, Fenaux, Pierre, Sanz, Guillermo, and Santini, Valeria

Published
2024
Full Text
View/download PDF

2. The Italian Multicentric Randomized OPTkIMA Trial on Fixed vs Progressive Intermittent TKI Therapy in CML Elderly Patients: 3-Years of Molecular Response and Quality of Life Monitoring After Completing the Treatment Plan

Author

Malagola, Michele, Iurlo, Alessandra, Bucelli, Cristina, Abruzzese, Elisabetta, Bonifacio, Massimiliano, Stagno, Fabio, Binotto, Gianni, D'Adda, Marienlla, Lunghi, Monia, Crugnola, Monica, Ferrari, Maria Luisa, Lunghi, Francesca, Castagnetti, Fausto, Rosti, Gianantonio, Lemoli, Roberto Massimo, Sancetta, Rosaria, Coppi, Maria Rosaria, Corsetti, Maria Teresa, De Gobbi, Marco, Romano, Atelda, Tiribelli, Mario, Russo Rossi, Antonella, Russo, Sabina, Defina, Marzia, Farina, Mirko, Bernardi, Simona, Butturini, Giulia, Pellizzeri, Simone, Roccaro, Aldo Maria, and Russo, Domenico

Published
2024
Full Text
View/download PDF

3. Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib

Author

Palandri, Francesca, Elli, Elena M., Auteri, Giuseppe, Bonifacio, Massimiliano, Benevolo, Giulia, Heidel, Florian H., Paglia, Simona, Trawinska, Malgorzata M., Bosi, Costanza, Rossi, Elena, Tiribelli, Mario, Tieghi, Alessia, Iurlo, Alessandra, Polverelli, Nicola, Caocci, Giovanni, Binotto, Gianni, Cavazzini, Francesco, Beggiato, Eloise, Cilloni, Daniela, Tatarelli, Caterina, Mendicino, Francesco, Miglino, Maurizio, Bocchia, Monica, Crugnola, Monica, Mazzoni, Camilla, Romagnoli, Andrea D., Rindone, Giovanni, Ceglie, Sara, D’Addio, Alessandra, Santoni, Eleonora, Cattaneo, Daniele, Bartoletti, Daniela, Lemoli, Roberto M., Krampera, Mauro, Cuneo, Antonio, Semenzato, Gianpietro C., Latagliata, Roberto, Abruzzese, Elisabetta, Vianelli, Nicola, Cavo, Michele, Andriani, Alessandro, De Stefano, Valerio, Palumbo, Giuseppe A., and Breccia, Massimo

Published
2023
Full Text
View/download PDF

4. Prednisone vs high-dose dexamethasone in newly diagnosed adult primary immune thrombocytopenia: a randomized trial

Author

Mazzucconi, Maria Gabriella, Rodeghiero, Francesco, Avvisati, Giuseppe, De Stefano, Valerio, Gugliotta, Luigi, Ruggeri, Marco, Vianelli, Nicola, Fazi, Paola, Paoloni, Francesca, Sargentini, Valeria, Baldacci, Erminia, Ferretti, Antonietta, Martino, Bruno, Vincelli, Iolanda Donatella, Carli, Giuseppe, Fortuna, Stefania, Di Ianni, Mauro, Ranalli, Paola, Palandri, Francesca, Polverelli, Nicola, Lugli, Elisabetta, Rivolti, Elena, Patriarca, Andrea, Rago, Angela, D’Adda, Mariella, Gentile, Massimo, Siragusa, Sergio, Sibilla, Silvia, Carella, Angelo Michele, Rossi, Elena, Battistini, Roberta, Zaja, Francesco, Bocchia, Monica, Di Renzo, Nicola, Musto, Pellegrino, Crugnola, Monica, Giuffrida, Anna Chiara, Krampera, Mauro, Tafuri, Agostino, and Santoro, Cristina

Published
2024
Full Text
View/download PDF

5. Hypocellular myelodysplastic syndromes (h-MDS): from clinical description to immunological characterization in the Italian multi-center experience

Author

Calabretto, Giulia, Attardi, Enrico, Teramo, Antonella, Trimarco, Valentina, Carraro, Samuela, Mossuto, Sandra, Barilà, Gregorio, Vicenzetto, Cristina, Gasparini, Vanessa Rebecca, Crugnola, Monica, Niscola, Pasquale, Poloni, Antonella, Giai, Valentina, Gaidano, Valentina, Finelli, Carlo, Bertorelle, Roberta, Candiotto, Cinzia, Pizzi, Marco, Binotto, Gianni, Facco, Monica, Vianello, Fabrizio, Trentin, Livio, Semenzato, Gianpietro, Zambello, Renato, and Santini, Valeria

Published
2022
Full Text
View/download PDF

6. Making Treatment-Free Remission (TFR) Easier in Chronic Myeloid Leukemia: Fact-Checking and Practical Management Tools

Author

Castagnetti, Fausto, Binotto, Gianni, Capodanno, Isabella, Billio, Atto, Calistri, Elisabetta, Cavazzini, Francesco, Crugnola, Monica, Gozzini, Antonella, Gugliotta, Gabriele, Krampera, Mauro, Lucchesi, Alessandro, Merli, Anna, Miggiano, Maria Cristina, Minotto, Claudia, Poggiaspalla, Monica, Salvucci, Marzia, Scappini, Barbara, Tiribelli, Mario, Trabacchi, Elena, Rosti, Gianantonio, Galimberti, Sara, and Bonifacio, Massimiliano

Published
2021
Full Text
View/download PDF

7. BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS

Author

Soverini, Simona, Martelli, Margherita, Bavaro, Luana, De Benedittis, Caterina, Sica, Simona, Sorà, Federica, Iurlo, Alessandra, Bonifacio, Massimiliano, Pregno, Patrizia, Galimberti, Sara, Lunghi, Francesca, Albano, Francesco, D’Adda, Mariella, Crugnola, Monica, Capodanno, Isabella, Castagnetti, Fausto, Gugliotta, Gabriele, Papayannidis, Cristina, Rosti, Gianantonio, Percesepe, Antonio, Mignone, Flavio, Baccarani, Michele, Martinelli, Giovanni, and Cavo, Michele

Published
2021
Full Text
View/download PDF

8. Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP

Author

Baccarani, Michele, Abruzzese, Elisabetta, Accurso, Vincenzo, Albano, Francesco, Annunziata, Mario, Barulli, Sara, Beltrami, Germana, Bergamaschi, Micaela, Binotto, Gianni, Bocchia, Monica, Caocci, Giovanni, Capodanno, Isabella, Cavazzini, Francesco, Cedrone, Michele, Cerrano, Marco, Crugnola, Monica, D'Adda, Mariella, Elena, Chiara, Fava, Carmen, Fazi, Paola, Fozza, Claudio, Galimberti, Sara, Giai, Valentina, Gozzini, Antonella, Gugliotta, Gabriele, Iurlo, Alessandra, La Barba, Gaetano, Levato, Luciano, Lucchesi, Alessandro, Luciano, Luigia, Lunghi, Francesca, Lunghi, Monia, Malagola, Michele, Marasca, Roberto, Martino, Bruno, Melpignano, Angela, Miggiano, Maria Cristina, Montefusco, Enrico, Musolino, Caterina, Palmieri, Fausto, Pregno, Patrizia, Rapezzi, Davide, Rege-Cambrin, Giovanna, Rupoli, Serena, Salvucci, Marzia, Sancetta, Rosaria, Sica, Simona, Spadano, Raffaele, Stagno, Fabio, Tiribelli, Mario, Tomassetti, Simona, Trabacchi, Elena, Bonifacio, Massimiliano, Breccia, Massimo, Castagnetti, Fausto, Pane, Fabrizio, Russo, Domenico, Saglio, Giuseppe, Soverini, Simona, Vigneri, Paolo, and Rosti, Gianantonio

Published
2019
Full Text
View/download PDF

9. Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy

Author

Efficace, Fabio, Stagno, Fabio, Iurlo, Alessandra, Breccia, Massimo, Cottone, Francesco, Bonifacio, Massimiliano, Abruzzese, Elisabetta, Castagnetti, Fausto, Caocci, Giovanni, Crugnola, Monica, Capodanno, Isabella, Martino, Bruno, Tiribelli, Mario, Patriarca, Andrea, Gozzini, Antonella, Pregno, Patrizia, Saussele, Susanne, Cascavilla, Nicola, Fozza, Claudio, Bergamaschi, Micaela, Binotto, Gianni, Vignetti, Marco, and Rosti, Gianantonio

Published
2020
Full Text
View/download PDF

10. Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy.

Author

Palandri, Francesca, Palumbo, Giuseppe A., Benevolo, Giulia, Iurlo, Alessandra, Elli, Elena M., Abruzzese, Elisabetta, Polverelli, Nicola, Tiribelli, Mario, Auteri, Giuseppe, Tieghi, Alessia, Caocci, Giovanni, Binotto, Gianni, Cavazzini, Francesco, Branzanti, Filippo, Beggiato, Eloise, Miglino, Maurizio, Bosi, Costanza, Crugnola, Monica, Bocchia, Monica, and Martino, Bruno

Subjects
MYELOFIBROSIS, RUXOLITINIB, ANEMIA, PROGRESSION-free survival
Abstract

Background: Anemia is frequently present in patients with myelofibrosis (MF), and it may be exacerbated by treatment with the JAK2‐inhibitor ruxolitinib (RUX). Recently, a relevant blast phase (BP) incidence has been reported in anemic MF patients unexposed to RUX. Methods: The authors investigated the incidence of BP in 886 RUX‐treated MF patients, included in the "RUX‐MF" retrospective study. Results: The BP incidence rate ratio (IRR) was 3.74 per 100 patient‐years (3.74 %p‐y). At therapy start, Common Terminology Criteria for Adverse Events grade 3‐4 anemia (hemoglobin [Hb] <8 g/dL) and severe sex/severity‐adjusted anemia (Hb <8/<9 g/dL in women/men) were present in 22.5% and 25% patients, respectively. IRR of BP was 2.34 in patients with no baseline anemia and reached respectively 4.22, 4.89, and 4.93 %p‐y in patients with grade 1, 2, and 3–4 anemia. Considering the sex/severity‐adjusted Hb thresholds, IRR of BP was 2.85, 4.97, and 4.89 %p‐y in patients with mild/no anemia, moderate, and severe anemia. Transfusion‐dependent patients had the highest IRR (5.03 %p‐y). Progression‐free survival at 5 years was 70%, 52%, 43%, and 27% in patients with no, grade 1, 2, and 3–4 anemia, respectively (p <.001). At 6 months, 260 of 289 patients with no baseline anemia were receiving ruxolitinib, and 9.2% had developed a grade 3–4 anemia. By 6‐month landmark analysis, BP‐free survival was significantly worse in patients acquiring grade 3–4 anemia (69.3% vs. 88.1% at 5 years, p <.001). Conclusions: This study highlights that anemia correlates with an increased risk of evolution into BP, both when present at baseline and when acquired during RUX monotherapy. Innovative anemia therapies and disease‐modifying agents are warranted in these patients. Anemia correlates with an increased risk of evolution into blast phase, both when present at baseline and when acquired during ruxolitinib monotherapy. Innovative anemia therapies and disease‐modifying agents are warranted in these patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. In Ph+BCR-ABL1P210+ acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent

Author

Baccarani, Michele, Iacobucci, Ilaria, Chiaretti, Sabina, Foà’, Robin, Balasubramanian, Poonkuzhali, Paietta, Elisabeth, Foroni, Letizia, Jeromin, Sabine, Izzo, Barbara, Spinelli, Orietta, Varma, Neelam, Menif, Samia, Terragna, Carolina, Seth, Tulika, Bidet, Audrey, Coriu, Daniel, Lunghi, Francesca, Mayer, Jiri, Scappini, Barbara, Langabeer, Stephen, Maier, Jacqueline, Burt, Emma, Candoni, Anna, Albano, Francesco, Luppi, Mario, Zupan, Irena, Lion, Thomas, Zadro, Renata, di Raimondo, Francesco, Poopak, Behzad, Rege-Cambrin, Giovanna, Annunziata, Mario, Ayala, Ana, Salinas-Viedma, Victor, Ines Prado, Ana, Milner, Benedict, Galimberti, Sara, Janssen, Jeroen, Polli, Valentina, Comba, Lorenzo, Borsellino, Beatrice, Annibali, Ombretta, Crugnola, Monica, and Passamonti, Francesco

Published
2020
Full Text
View/download PDF

13. Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline

Author

Crugnola, Monica, Castagnetti, Fausto, Breccia, Massimo, Ferrero, Dario, Trawinska, Malgorzata Monika, Abruzzese, Elisabetta, Annunziata, Mario, Stagno, Fabio, Tiribelli, Mario, Binotto, Gianni, Bonifacio, Massimiliano, Fava, Carmen, Iurlo, Alessandra, Bucelli, Cristina, Mansueto, Giovanna, Gozzini, Antonella, Falzetti, Franca, Montefusco, Enrico, Crisà, Elena, Gugliotta, Gabriele, Russo, Sabina, Cedrone, Michele, RussoRossi, Antonella, Pregno, Patrizia, Isidori, Alessandro, Mauro, Endri, Atelda, Romano, Giglio, Gianfranco, Celesti, Francesca, Sorà, Federica, Storti, Sergio, D’Addosio, Adam, Galimberti, Sara, Orlandi, Ester, Calistri, Elisabetta, Bocchia, Monica, Cavazzini, Francesco, Rege Cambrin, Giovanna, Orofino, Nicola, Luciano, Luigiana, Sgherza, Nicola, Rosti, Gianantonio, Latagliata, Roberto, and Capodanno, Isabella

Published
2019
Full Text
View/download PDF

14. Haploidentical hematopoietic stem cell transplantation in adults using the αβTCR/CD19-based depletion of G-CSF-mobilized peripheral blood progenitor cells

Author

Prezioso, Lucia, Manfra, Ilenia, Bonomini, Sabrina, Schifano, Chiara, Segreto, Roberta, Monti, Alessandro, Sammarelli, Gabriella, Todaro, Giannalisa, Sassi, Maria, Bertaggia, Ilaria, Pelagatti, Laura, Cambò, Benedetta, Spolzino, Angelica, Follini, Elena, Re, Francesca, Crugnola, Monica, Craviotto, Luisa, Russo, Filomena, Plenteda, Caterina, Roti, Giovanni, Giuliani, Nicola, and Aversa, Franco

Published
2019
Full Text
View/download PDF

15. Health-related quality of life, symptom burden, and comorbidity in long-term survivors of acute promyelocytic leukemia

Author

Efficace, Fabio, Breccia, Massimo, Avvisati, Giuseppe, Cottone, Francesco, Intermesoli, Tamara, Borlenghi, Erika, Carluccio, Paola, Rodeghiero, Francesco, Fabbiano, Francesco, Luppi, Mario, Romani, Claudio, Sborgia, Marco, D’Ardia, Stefano, Nobile, Francesco, Cantore, Nicola, Crugnola, Monica, Nadali, Gianpaolo, Vignetti, Marco, Amadori, Sergio, and Lo Coco, Francesco

Published
2019
Full Text
View/download PDF

16. Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib

Author

Breccia, Massimo, Bartoletti, Daniela, Bonifacio, Massimiliano, Palumbo, Giuseppe A., Polverelli, Nicola, Abruzzese, Elisabetta, Bergamaschi, Micaela, Tieghi, Alessia, Tiribelli, Mario, Iurlo, Alessandra, Cavazzini, Francesco, Sgherza, Nicola, Binotto, Gianni, Isidori, Alessandro, D’Adda, Mariella, Crugnola, Monica, Bosi, Costanza, Heidel, Florian, Molica, Matteo, Scaffidi, Luigi, Cattaneo, Daniele, Latagliata, Roberto, Auteri, Giuseppe, Lemoli, Roberto M., Fanin, Renato, Russo, Domenico, Aversa, Franco, Cuneo, Antonio, Semenzato, Gianpietro, Catani, Lucia, Cavo, Michele, Vianelli, Nicola, Foà, Robin, and Palandri, Francesca

Published
2019
Full Text
View/download PDF

17. Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis

Author

Palandri, Francesca, Palumbo, Giuseppe Alberto, Elli, Elena Maria, Polverelli, Nicola, Benevolo, Giulia, Martino, Bruno, Abruzzese, Elisabetta, Tiribelli, Mario, Tieghi, Alessia, Latagliata, Roberto, Cavazzini, Francesco, Bergamaschi, Micaela, Binotto, Gianni, Crugnola, Monica, Isidori, Alessandro, Caocci, Giovanni, Heidel, Florian, Pugliese, Novella, Bosi, Costanza, Bartoletti, Daniela, Auteri, Giuseppe, Cattaneo, Daniele, Scaffidi, Luigi, Trawinska, Malgorzata Monica, Stella, Rossella, Ciantia, Fiorella, Pane, Fabrizio, Cuneo, Antonio, Krampera, Mauro, Semenzato, Gianpietro, Lemoli, Roberto Massimo, Iurlo, Alessandra, Vianelli, Nicola, Cavo, Michele, Breccia, Massimo, and Bonifacio, Massimiliano

Published
2021
Full Text
View/download PDF

18. Iron overload alters the energy metabolism in patients with myelodysplastic syndromes: results from the multicenter FISM BIOFER study

Author

Cilloni, Daniela, Ravera, Silvia, Calabrese, Chiara, Gaidano, Valentina, Niscola, Pasquale, Balleari, Enrico, Gallo, Daniela, Petiti, Jessica, Signorino, Elisabetta, Rosso, Valentina, Panuzzo, Cristina, Sabatini, Federica, Andreani, Giacomo, Dragani, Matteo, Finelli, Carlo, Poloni, Antonella, Crugnola, Monica, Voso, Maria Teresa, Fenu, Susanna, Pelizzari, Annamaria, Santini, Valeria, Saglio, Giuseppe, Podestà, Marina, and Frassoni, Francesco

Published
2020
Full Text
View/download PDF

19. Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice

Author

Breccia, Massimo, Abruzzese, Elisabetta, Castagnetti, Fausto, Bonifacio, Massimiliano, Gangemi, Domenica, Sorà, Federica, Iurlo, Alessandra, Luciano, Luigiana, Gozzini, Antonella, Gentile, Massimo, Bocchia, Monica, Luzi, Debora, Maggi, Alessandro, Sgherza, Nicola, Isidori, Alessandro, Crugnola, Monica, Pregno, Patrizia, Scortechini, Anna Rita, Capodanno, Isabella, Pizzuti, Michele, and Foà, Robin

Published
2018
Full Text
View/download PDF

20. Frontline Dasatinib Treatment in a “Real-Life” Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia

Author

Latagliata, Roberto, Stagno, Fabio, Annunziata, Mario, Abruzzese, Elisabetta, Iurlo, Alessandra, Guarini, Attilio, Fava, Carmen, Gozzini, Antonella, Bonifacio, Massimiliano, Sorà, Federica, Leonetti Crescenzi, Sabrina, Bocchia, Monica, Crugnola, Monica, Castagnetti, Fausto, Capodanno, Isabella, Galimberti, Sara, Feo, Costanzo, Porrini, Raffaele, Pregno, Patrizia, Rizzo, Manuela, Antolino, Agostino, Mauro, Endri, Sgherza, Nicola, Luciano, Luigiana, Tiribelli, Mario, Russo Rossi, Antonella, Trawinska, Malgorzata, Vigneri, Paolo, Breccia, Massimo, Rosti, Gianantonio, and Alimena, Giuliana

Published
2016
Full Text
View/download PDF

21. Dasatinib first-line: Multicentric Italian experience outside clinical trials

Author

Breccia, Massimo, Stagno, Fabio, Luciano, Luigiana, Abruzzese, Elisabetta, Annunziata, Mario, D’Adda, Mariella, Maggi, Alessandro, Sgherza, Nicola, Russo-Rossi, Antonella, Pregno, Patrizia, Castagnetti, Fausto, Iurlo, Alessandra, Latagliata, Roberto, Cedrone, Michele, Di Renzo, Nicola, Sorà, Federica, Rege-Cambrin, Giovanna, La Nasa, Giorgio, Scortechini, Anna Rita, Greco, Giovanna, Franceschini, Luca, Sica, Simona, Bocchia, Monica, Crugnola, Monica, Orlandi, Esther, Guarini, Attilio, Specchia, Giorgina, Rosti, Gianantonio, Saglio, Giuseppe, and Alimena, Giuliana

Published
2016
Full Text
View/download PDF

22. A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis.

Author

Palandri, Francesca, Palumbo, Giuseppe A., Bonifacio, Massimiliano, Elli, Elena M., Tiribelli, Mario, Auteri, Giuseppe, Trawinska, Malgorzata M., Polverelli, Nicola, Benevolo, Giulia, Tieghi, Alessia, Cavalca, Fabrizio, Caocci, Giovanni, Beggiato, Eloise, Binotto, Gianni, Cavazzini, Francesco, Miglino, Maurizio, Bosi, Costanza, Crugnola, Monica, Bocchia, Monica, and Martino, Bruno

Subjects
MYELOFIBROSIS, TIME, MULTIVARIATE analysis, RETROSPECTIVE studies, JANUS kinases, RISK assessment, TREATMENT failure, DRUG therapy, RESEARCH funding, NEUROTRANSMITTER uptake inhibitors, OVERALL survival
Abstract

Simple Summary: Despite significant clinical activity, 50% to 70% of patients discontinue ruxolitinib within 3 to 5 years. The identification of patients who are more likely to discontinue it early has now become of paramount practical importance, given the availability of new drugs that are either approved (i.e., fedratinib, pacritinib, and momelotinib) or undergoing advanced clinical investigation for patients with a suboptimal response or ruxolitinib resistance (i.e., navitoclax, pelabresib, and imetelstat). A retrospective, real-world analysis was performed on 889 MF patients treated with ruxolitinib from the observational "RUX-MF" Italian study. We investigated predictors of early ruxolitinib discontinuation and death on therapy in 889 MF patients. Results confirm that prolonged ruxolitinib administration is associated with improved OS when compared to earlier discontinuation. While this outcome may be expected at the 5-year timepoint, interestingly, the survival advantage was observed also categorizing patients at earlier timepoints. Most patients with myelofibrosis (MF) discontinue ruxolitinib (JAK1/JAK2 inhibitor) in the first 5 years of therapy due to therapy failure. As the therapeutic possibilities of MF are expanding, it is critical to identify patients predisposed to early ruxolitinib monotherapy failure and worse outcomes. We investigated predictors of early ruxolitinib discontinuation and death on therapy in 889 patients included in the "RUX-MF" retrospective study. Overall, 172 patients were alive on ruxolitinib after ≥5 years (long-term ruxolitinib, LTR), 115 patients were alive but off ruxolitinib after ≥5 yrs (short-term RUX, STR), and 123 patients died while on ruxolitinib after <5 yrs (early death on ruxolitinib, EDR). The cumulative incidence of the blast phase was similar in LTR and STR patients (p = 0.08). Overall survival (OS) was significantly longer in LTR pts (p = 0.002). In multivariate analysis, PLT < 100 × 109/L, Hb < 10 g/dL, primary MF, absence of spleen response at 3 months and ruxolitinib starting dose <10 mg BID were associated with higher probability of STR. Assigning one point to each significant variable, a prognostic model for STR (STR-PM) was built, and three groups were identified: low (score 0–1), intermediate (score 2), and high risk (score ≥ 3). The STR-PM may identify patients at higher risk of failure with ruxolitinib monotherapy who should be considered for alternative frontline strategies. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

23. Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients

Author

Breccia, Massimo, Efficace, Fabio, Sica, Simona, Abruzzese, Elisabetta, Cedrone, Michele, Turri, Diamante, Gobbi, Marco, Carella, Angelo Michele, Gozzini, Antonella, Usala, Emilio, Cavazzini, Francesco, Danise, Paolo, Tiribelli, Mario, Binotto, Gianni, Pregno, Patrizia, Bocchia, Monica, Gaidano, Gianluca, Crugnola, Monica, Bonifacio, Massimiliano, Avanzini, Paolo, Celesti, Francesca, Guella, Anna, Martino, Bruno, Annunziata, Mario, Luciano, Luigiana, Stagno, Fabio, Vallisa, Daniele, Pungolino, Esther, Iurlo, Alessandra, Rambaldi, Alessandro, Nardiello, Ida, Orlandi, Esther, Gambacorti-Passerini, Carlo, and Alimena, Giuliana

Published
2015
Full Text
View/download PDF

24. Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study.

Author

Palandri, Francesca, Rossi, Elena, Auteri, Giuseppe, Breccia, Massimo, Paglia, Simona, Benevolo, Giulia, Elli, Elena M., Cavazzini, Francesco, Binotto, Gianni, Tieghi, Alessia, Tiribelli, Mario, Heidel, Florian H., Bonifacio, Massimiliano, Pugliese, Novella, Caocci, Giovanni, Crugnola, Monica, Mendicino, Francesco, D'Addio, Alessandra, Tomassetti, Simona, and Martino, Bruno

Subjects
POLYCYTHEMIA vera, HYDROXYUREA, MULTIVARIATE analysis, JANUS kinases, TREATMENT effectiveness, DESCRIPTIVE statistics, RESEARCH funding, NEUROTRANSMITTER uptake inhibitors, DRUG side effects, DRUG resistance in cancer cells
Abstract

Simple Summary: The prognostic relevance of a patient achieving complete response to hydroxyurea, the predictors of response, and patients' triggers for switching to ruxolitinib are uncertain. A retrospective, real-world analysis was performed on 563 polycythemia vera patients treated with hydroxyurea for ≥12 months during an observational "PV-NET" Italian study. We investigated factors associated with a complete response to hydroxyurea and outcomes of the 397 poor responders to hydroxyurea according to whether they subsequently received ruxolitinib (n = 114) or continued hydroxyurea (n = 283). The results suggest that many PV patients receive underdosed hydroxyurea, leading to lower response and toxicity rates. In addition, many patients continued hydroxyurea despite a poor clinical or hematological response; however, splenomegaly and other symptoms were the main drivers of an early switch. Better HU management, standardization of the criteria for and timing of responses to HU, and adequate intervention in poor responders should be advised. In polycythemia vera (PV), the prognostic relevance of an ELN-defined complete response (CR) to hydroxyurea (HU), the predictors of response, and patients' triggers for switching to ruxolitinib are uncertain. In a real-world analysis, we evaluated the predictors of response, their impact on the clinical outcomes of CR to HU, and the correlations between partial or no response (PR/NR) and a patient switching to ruxolitinib. Among 563 PV patients receiving HU for ≥12 months, 166 (29.5%) achieved CR, 264 achieved PR, and 133 achieved NR. In a multivariate analysis, the absence of splenomegaly (p = 0.03), pruritus (p = 0.002), and a median HU dose of ≥1 g/day (p < 0.001) remained associated with CR. Adverse events were more frequent with a median HU dose of ≥1 g/day. Overall, 283 PR/NR patients (71.3%) continued HU, and 114 switched to ruxolitinib. In the 449 patients receiving only HU, rates of thrombosis, hemorrhages, progression, and overall survival were comparable among the CR, PR, and NR groups. Many PV patients received underdosed HU, leading to lower CR and toxicity rates. In addition, many patients continued HU despite a PR/NR; however, splenomegaly and other symptoms were the main drivers of an early switch. Better HU management, standardization of the criteria for and timing of responses to HU, and adequate intervention in poor responders should be advised. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

25. Prospective monitoring of chronic myeloid leukemia patients from the time of TKI discontinuation: the fate of peripheral blood CD26+ leukemia stem cells.

Author

Pacelli, Paola, Santoni, Adele, Sicuranza, Anna, Abruzzese, Elisabetta, Giai, Valentina, Crugnola, Monica, Annunziata, Mario, Galimberti, Sara, Iurlo, Alessandra, Luciano, Luigiana, Sorà, Federica, Fava, Carmen, Bestoso, Elena, Marzano, Cristina, Cartocci, Alessandra, Defina, Marzia, Sammartano, Vincenzo, Cencini, Emanuele, Raspadori, Donatella, and Bocchia, Monica

Subjects
CHRONIC myeloid leukemia, STEM cells, LEUKEMIA, PROTEIN-tyrosine kinase inhibitors, DISEASE relapse
Abstract

Introduction: In chronic myeloid leukemia (CML), about half of the patients achieving a deep and stable molecular response with tyrosine kinase inhibitors (TKIs) may discontinue TKI treatment without disease recurrence. As such, treatment-free remission (TFR) has become an ambitious goal of treatment. Given the evidence that deepness and duration of molecular response are necessary but not sufficient requisites for a successful TFR, additional biological criteria are needed to identify CML patients suitable for efficacious discontinuation. Leukemia stem cells (LSCs) are supposed to be the reservoir of the disease. Previously, we demonstrated that residual circulating CD34+/CD38-/CD26+ LSCs were still detectable in a consistent number of CML patients during TFR. Methods: CML LSCs could be easily identified by flow-cytometry as they express the CD34+/CD38-/CD26+ phenotype. In this study, we explored the role of these cells and their correlation with molecular response in a cohort of 109 consecutive chronic phase CML patients prospectively monitored from the time of TKI discontinuation. Results: After a median observation time of 33 months from TKI discontinuation, 38/109 (35%) patients failed TFR after a median time of 4 months, while 71/109 (65%) patients are still in TFR. At TKI discontinuation, peripheral blood CD26+LSCs were undetectable in 48/109 (44%) patients and detectable in 61/109 (56%). No statistically significant correlation between detectable/undetectable CD26+LSCs and the rate of TFR loss was found (p = 0.616). The incidence of TFR loss based on the type of TKI treatment was statistically significant for imatinib treatment compared to that of nilotinib (p = 0.039). Exploring the behavior of CD26+LSCs during TFR, we observed fluctuating values that were very variable between patients, and they were not predictive of TFR loss. Discussion: Up to date, our results confirm that CD26+LSCs are detectable at the time of TKI discontinuation and during TFR. Moreover, at least for the observation median time of the study, the persistence of "fluctuating" values of residual CD26+LSCs does not hamper the possibility to maintain a stable TFR. On the contrary, even patients discontinuing TKI with undetectable CD26+LSCs could undergo TFR loss. Our results suggest that factors other than residual LSCs "burden" playing an active role in controlling disease recurrence. Additional studies evaluating CD26+LSCs' ability to modulate the immune system and their interaction in CML patients with very long stable TFR are ongoing. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

26. Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome.

Author

Palandri, Francesca, Breccia, Massimo, Mazzoni, Camilla, Auteri, Giuseppe, Elli, Elena Maria, Trawinska, Malgorzata M., Polverelli, Nicola, Tiribelli, Mario, Benevolo, Giulia, Iurlo, Alessandra, Tieghi, Alessia, Heidel, Florian H., Caocci, Giovanni, Beggiato, Eloise, Binotto, Gianni, Cavazzini, Francesco, Miglino, Maurizio, Bosi, Costanza, Crugnola, Monica, and Bocchia, Monica

Subjects
MYELOFIBROSIS, RUXOLITINIB, POLYCYTHEMIA vera, LEUKOCYTE count, PROGNOSTIC models, REGRESSION analysis
Abstract

Background: Patients with cytopenic myelofibrosis (MF) have more limited therapeutic options and poorer prognoses compared with patients with the myeloproliferative phenotype. Aims and Methods: Prognostic correlates of cytopenic phenotype were explored in 886 ruxolitinib‐treated patients with primary/secondary MF (PMF/SMF) included in the RUX‐MF retrospective study. Cytopenia was defined as: leukocyte count <4 × 109/L and/or hemoglobin <11/<10 g/dL (males/females) and/or platelets <100 × 109/L. Results: Overall, 407 (45.9%) patients had a cytopenic MF, including 249 (52.4%) with PMF. In multivariable analysis, high molecular risk mutations (p =.04), intermediate 2/high Dynamic International Prognostic Score System (p <.001) and intermediate 2/high Myelofibrosis Secondary to Polycythemia Vera and Essential Thrombocythemia Prognostic Model (p <.001) remained associated with cytopenic MF in the overall cohort, PMF, and SMF, respectively. Patients with cytopenia received lower average ruxolitinib at the starting (25.2 mg/day vs. 30.2 mg/day, p <.001) and overall doses (23.6 mg/day vs. 26.8 mg/day, p <.001) and achieved lower rates of spleen (26.5% vs. 34.1%, p =.04) and symptom (59.8% vs. 68.8%, p =.008) responses at 6 months compared with patients with the proliferative phenotype. Patients with cytopenia also had higher rates of thrombocytopenia at 3 months (31.1% vs. 18.8%, p <.001) but lower rates of anemia (65.6% vs. 57.7%, p =.02 at 3 months and 56.6% vs. 23.9% at 6 months, p <.001). After competing risk analysis, the cumulative incidence of ruxolitinib discontinuation at 5 years was 57% and 38% in patients with cytopenia and the proliferative phenotype (p <.001), whereas cumulative incidence of leukemic transformation was similar (p =.06). In Cox regression analysis adjusted for Dynamic International Prognostic Score System score, survival was significantly shorter in patients with cytopenia (p <.001). Conclusions: Cytopenic MF has a lower probability of therapeutic success with ruxolitinib as monotherapy and worse outcome. These patients should be considered for alternative therapeutic strategies. Cytopenic myelofibrosis has a lower probability of therapeutic success with ruxolitinib as monotherapy and worse outcome. Patients with cytopenic myelofibrosis should be considered for alternative therapeutic strategies. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

27. Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Treatment of Myeloproliferative Neoplasms in Blastic Phase (MPN-BP) and Acute Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine

Author

Latagliata, Roberto, Cristiano, Gianluca, Lama, Dorela, Fenu, Susanna, Rizzo, Lorenzo, Cambò, Benedetta, Zoletto, Simone, Spirito, Francesca, Cavalca, Fabrizio, Cattaneo, Daniele, Cenfra, Natalia, De Luca, Giulia, Esposito Vangone, Beatrice, Di Veroli, Ambra, Palmieri, Raffaele, Annunziata, Mario, Mulas, Olga, Abruzzese, Elisabetta, Molteni, Alfredo, Piedimonte, Monica, Carmosino, Ida, Salutari, Prassede, Biagi, Annalisa, Bocchia, Monica, Santopietro, Michelina, Binotto, Gianni, Iurlo, Alessandra, Crugnola, Monica, Riva, Marta, Piccioni, Anna Lina, Elli, Elena Maria, Curti, Antonio, and Poloni, Antonella

Published
2022
Full Text
View/download PDF

28. Choice of Tyrosine Kinase Inhibitor and Early Events during the First Year of Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) Patients with Concomitant Diabetes: A "Campus CML" Study

Author

Capodanno, Isabella, Tiribelli, Mario, Miggiano, Maria Cristina, Bucelli, Cristina, Cavazzini, Francesco, Leonetti Crescenzi, Sabrina, Russo, Sabina, Scalzulli, Emilia, Bernardelli, Andrea, Luciano, Luigiana, Mulas, Olga, Loglisci, Giuseppina, Elena, Chiara, Pizzano, Umberto, Attolico, Immacolata, Binotto, Gianni, Crisà, Elena, Sportoletti, Paolo, Di Veroli, Ambra, Scortechini, Anna Rita, Leporace, Annapaola, Basile, Maria, Crugnola, Monica, Stagno, Fabio, Murgano, Pamela, Rapezzi, Davide, Luzi, Debora, Iurlo, Alessandra, Bocchia, Monica, Fava, Carmen, Malato, Alessandra, Galimberti, Sara, Vincelli, Iolanda Donatella, Trawinska, Malgorzata Monika, Pizzuti, Michele, Caocci, Giovanni, Bonifacio, Massimiliano, Saglio, Giuseppe, Specchia, Giorgina, Breccia, Massimo, and Latagliata, Roberto

Published
2022
Full Text
View/download PDF

29. Dosing Pattern of Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) in Italy: Results from a Prospective Observational Study (ROMEI)

Author

Breccia, Massimo, Guglielmelli, Paola, Mendicino, Francesco, Malato, Alessandra, Palumbo, Giuseppe A., Selleri, Carmine, Cilloni, Daniela, Mazza, Patrizio, Siragusa, Sergio, Abruzzese, Elisabetta, Martelli, Maurizio, Benevolo, Giulia, Rinaldi, Erminia, Crugnola, Monica, Rupoli, Serena, Pavone, Vincenzo, Bonifacio, Massimiliano, Pane, Fabrizio, Carli, Giuseppe, Langella, Maria, Bruno Ventre, Marta, Elli, Elena Maria, Impera, Stefana, Liberati, Anna Marina, Di Renzo, Nicola, Martino, Bruno, Sportoletti, Paolo, Tiribelli, Mario, Binotto, Gianni, Annunziata, Mario, Di Ianni, Mauro, La Nasa, Giorgio, Falcone, Antonietta Pia, Leanza, Rossana, Volpe, Antonio, Gherlinzoni, Filippo, De Stefano, Valerio, Vallisa, Daniele, Leonetti Crescenzi, Sabrina, Cavazzini, Francesco, Ricco, Alessandra, Barberio, Carmela, Misto, Alessandra, Passamonti, Francesco, and Palandri, Francesca

Published
2022
Full Text
View/download PDF

30. A population‐based study of chronic myeloid leukemia patients treated with imatinib in first line

Author

Castagnetti, Fausto, Di Raimondo, Francesco, De Vivo, Antonio, Spitaleri, Antonio, Gugliotta, Gabriele, Fabbiano, Francesco, Capodanno, Isabella, Mannina, Donato, Salvucci, Marzia, Antolino, Agostino, Marasca, Roberto, Musso, Maurizio, Crugnola, Monica, Impera, Stefana, Trabacchi, Elena, Musolino, Caterina, Cavazzini, Francesco, Mineo, Giuseppe, Tosi, Patrizia, Tomaselli, Carmela, Rizzo, Michele, Siragusa, Sergio, Fogli, Miriam, Ragionieri, Riccardo, Zironi, Alessandro, Soverini, Simona, Martinelli, Giovanni, Cavo, Michele, Vigneri, Paolo, Stagno, Fabio, Rosti, Gianantonio, and Baccarani, Michele

Published
2017
Full Text
View/download PDF

31. P686: REAL‐WORLD EFFICACY PROFILE OF ASCIMINIB IN AN ITALIAN, MULTI‐RESISTANT CHRONIC‐PHASE CHRONIC MYELOID LEUKEMIA (CP‐CML) PATIENT POPULATION.

Author

Breccia, Massimo, Russo Rossi, Antonella, Giai, Valentina, Martino, Bruno, Fava, Carmen, Annunziata, Mario, Abruzzese, Elisabetta, Binotto, Gianni, Baratè, Claudia, Pio Nardozza, Aurelio, Misto, Alessandra, Coco, Paola, Calafiore, Valeria, Cristina Carraro, Maria, Cattina, Federica, Cavazzini, Francesco, Teresa Corsetti, Maria, Crucitti, Lara, Crugnola, Monica, and Ditonno, Paolo

Published
2023
Full Text
View/download PDF

32. Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia

Author

Gugliotta, Luigi, Tieghi, Alessia, Tortorella, Giovanni, Scalzulli, Potito Rosario, Ciancia, Rosanna, Lunghi, Monia, Cacciola, Emma, Cacciola, Rossella, Candoni, Anna, Crugnola, Monica, Codeluppi, Katia, Usala, Emilio, Specchia, Giorgina, Martinelli, Vincenzo, Palmieri, Fausto, Pierri, Ivana, Liberati, Anna Marina, Iurlo, Alessandra, Grossi, Alberto, Vannucchi, Alessandro M., Vianelli, Nicola, and Mazzucconi, Maria Gabriella

Published
2011
Full Text
View/download PDF

33. Association of Hypomethylating Agents + Venetoclax in the Real-Life Treatment of Myeloproliferative Neoplasms in Blastic Phase

Author

Latagliata, Roberto, Cristiano, Gianluca, Lame, Dorela, Strazimiri, Alda, Cavalca, Fabrizio, Rizzo, Lorenzo, De Luca, Giulia, Zoletto, Simone, Federico, Vincenzo, Cattaneo, Daniele, Biagi, Annalisa, Crugnola, Monica, Niscola, Pasquale, Palmieri, Raffaele, Piccioni, Anna Lina, Mulas, Olga, Esposito Vangone, Beatrice, Santopietro, Michelina, Carmosino, Ida, Iurlo, Alessandra, Di Rienzo, Nicola, Binotto, Gianni, Salutari, Prassede, Riva, Marta, Bonifacio, Massimiliano, Elli, Elena Maria, Curti, Antonio, and Poloni, Antonella

Published
2023
Full Text
View/download PDF

34. Imatinib in Very Elderly Patients with Chronic Myeloid Leukemia in Chronic Phase: A Retrospective Study

Author

Latagliata, Roberto, Ferrero, Dario, Iurlo, Alessandra, Cavazzini, Francesco, Castagnetti, Fausto, Abruzzese, Elisabetta, Fava, Carmen, Breccia, Massimo, Annunziata, Mario, Stagno, Fabio, Tiribelli, Mario, Binotto, Gianni, Mansueto, Giovanna, Gozzini, Antonella, Russo, Sabina, Cavalli, Laura, Montefusco, Enrico, Gugliotta, Gabriele, Cedrone, Michele, Russo Rossi, Antonella, Avanzini, Paolo, Pregno, Patrizia, Mauro, Endri, Spadea, Antonio, Celesti, Francesca, Giglio, Gianfranco, Isidori, Alessandro, Crugnola, Monica, Calistri, Elisabetta, Sorà, Federica, Storti, Stefano, D’Addosio, Ada, Rege-Cambrin, Giovanna, Luciano, Luigiana, and Alimena, Giuliana

Published
2013
Full Text
View/download PDF

35. Molecular response and Quality of Life (QoL) in Chronic Myeloid Leukemia (CML) patients treated with Intermittent TKIs: first interim analysis of OPTkIMA Study

Author

Michele Malagola, Iurlo, Alessandra, Abruzzese, Elisabetta, Bonifacio, Massimiliano, Stagno, Fabio, Binotto, Gianni, D’adda, Mariella, Lunghi, Monia, Crugnola, Monica, Ferrari Maria Luisa, Lunghi, Francesca, Castagnetti, Fausto, Rosti, Gianantonio, Lemoli Roberto Massimo, Sancetta, Rosaria, Coppi Maria Rosaria, Corsetti Maria Teresa, Rege Cambrin Giovanna, Romano, Atelda, Tiribelli, Mario, Russo Rossi Antonella, Russo, Sabina, Aprile, Lara, Gandolfi, Lisa, Mirko Farina, Simona Bernardi, Polverelli, Nicola, Roccaro, Aldo Maria, De Vivo Antonio, Baccarani, Michele, and Russo, Domenico

Published
2021

37. COVID‐19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report.

Author

Breccia, Massimo, Abruzzese, Elisabetta, Accurso, Vincenzo, Attolico, Immacolata, Barulli, Sara, Bergamaschi, Micaela, Binotto, Gianni, Bocchia, Monica, Bonifacio, Massimiliano, Caocci, Giovanni, Capodanno, Isabella, Castagnetti, Fausto, Cavazzini, Francesco, Crisà, Elena, Crugnola, Monica, Stella De Candia, Maria, Elena, Chiara, Fava, Carmen, Galimberti, Sara, and Gozzini, Antonella

Subjects
CHRONIC myeloid leukemia, COVID-19, CHRONIC leukemia, PROTEIN-tyrosine kinase inhibitors, INTENSIVE care units, COVID-19 pandemic
Abstract

Summary: Limited information is available on the impact of the COVID‐19 pandemic on the management of chronic myeloid leukaemia (CML). The Campus CML network collected retrospective information on 8 665 CML patients followed at 46 centres throughout Italy during the pandemic between February 2020 and January 2021. Within this cohort, we recorded 217 SARS‐CoV‐2‐positive patients (2·5%). Most patients (57%) were diagnosed as having SARS‐CoV‐2 infection during the second peak of the pandemic (September 2020 to January 2021). The majority (35%) was aged between 50 and 65 years with a male prevalence (73%). Fifty‐six percent of patients presented concomitant comorbidities. The median time from CML diagnosis to SARS‐CoV‐2 infection was six years (three months to 18 years). Twenty‐one patients (9·6%) required hospitalization without the need of respiratory assistance, 18 (8·2%) were hospitalized for respiratory assistance, 8 (3·6%) were admitted to an intensive care unit, while 170 (78%) were only quarantined. Twenty‐three percent of patients discontinued tyrosine kinase inhibitor (TKI) therapy during the infection. Twelve patients died due to COVID‐19 with a mortality rate of 5·5% in the positive cohort and of 0·13% in the whole cohort. We could also document sequelae caused by the SARS‐CoV‐2 infection and an impact of the pandemic on the overall management of CML patients. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

38. Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study.

Author

Stagno, Fabio, Breccia, Massimo, Annunziata, Mario, Trawinska, Malgorzata Monika, Iurlo, Alessandra, Sgherza, Nicola, Fava, Carmen, Gozzini, Antonella, Luciano, Luigiana, Carmosino, Ida, Bonifacio, Massimiliano, Sorà, Federica, Leonetti Crescenzi, Sabrina, Crugnola, Monica, Gugliotta, Gabriele, Galimberti, Sara, Bucelli, Cristina, Colafigli, Gioia, Feo, Costanzo, and Tiribelli, Mario

Subjects
SURVIVAL, SCIENTIFIC observation, CONFIDENCE intervals, CHRONIC myeloid leukemia, RETROSPECTIVE studies, PROTEIN-tyrosine kinase inhibitors, CANCER patients, DESCRIPTIVE statistics, DASATINIB, LONGITUDINAL method, DRUG toxicity, OLD age
Abstract

A limited amount of data has been published in chronic-phase chronic myeloid leukemia (CP-CML) patients aged >75 years treated frontline with second-generation tyrosine kinase inhibitors. To address this issue in a clinical 'real-life' setting, we retrospectively analyzed 45 CP-CML patients (pts) followed in 20 Italian Centers and treated frontline with dasatinib (DAS). Median age was 78.4 years (range 75–89.2 years). DAS starting dose was 100 mg QD in 35 pts (77.7%), 80 mg QD in 1 pts (2.2%) and 50 mg QD in 9 pts (20.1%), respectively. The median follow-up was 42.6 months (IQR 20.4 − 63.3). Grade 3 and 4 side effects, both hematological and non-hematological, were detected in 6 (13.3%) and 12 (26.6%) pts, respectively. Pleural effusions of all grades occurred in 13 pts (28.8%) after a median period of DAS exposure of 14.7 months (IQR 3.0 − 33.1). The rates of DAS dose reduction and permanent drug discontinuation were 53.3% and 20.0%, respectively. As the best response, 42/45 patients (93.3%) achieved a complete cytogenetic response (CCyR), 35/45 (77.7%) a major molecular response (MMR) and 24/45 (53.3%) a deep molecular response (both MR 4.0 and MR 4.5). Only 1 patient (2.2%) progressed to the blast phase after 13 months of therapy; 8 deaths were observed (1 CML-related and 7 CML-unrelated). Cumulative event-free survival and overall survival at 36 months were 64.7% (95%, CI 49.4 − 80.0) and 82.3% (95%, CI 70.3–94.3), respectively. These findings, although evaluated in a limited and selected cohort of patients, suggest that DAS might be effective in older patients (aged >75 years) affected by CP-CML with acceptable toxicity. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

40. Permanent Discontinuation of Tyrosine Kinase Inhibitor Frontline Therapy in Patients with Chronic Phase Chronic Myeloid Leukemia Patients during the First 36 Months of Treatment: A "Campus CML" Study

Author

Latagliata, Roberto, Capodanno, Isabella, Miggiano, Maria Cristina, Iurlo, Alessandra, Cavazzini, Francesco, Leonetti Crescenzi, Sabrina, Russo, Sabina, Carmosino, Ida, Bernardelli, Andrea, Mulas, Olga, Elena, Chiara, Binotto, Gianni, Crisà, Elena, Di Veroli, Ambra, Scortechini, Anna Rita, Basile, Maria, Crugnola, Monica, Murgano, Pamela, Pizzuti, Michele, Bucelli, Cristina, Fava, Carmen, Dalmazzo, Matteo, Lunghi, Francesca, Caocci, Giovanni, Bonifacio, Massimiliano, Saglio, Giuseppe, Specchia, Giorgina, Breccia, Massimo, and Tiribelli, Mario

Published
2022
Full Text
View/download PDF

41. Enestpath Leukemic Stem Cell (LSC) Sub-Study: Analyzing Characteristics of LSC-Positive Patients and Impact of Switch from Imatinib to Nilotinib Therapy on LSCs in Patients with Chronic Myeloid Leukemia

Author

Sanchez-Guijo, Fermin Matarraz, Sergio Plata, Eleni Sagues, Miguel Cortes, Montserrat Zupan, Irena Preloznik Crugnola, Monica Caocci, Giovanni Oakervee, Heather Gedde-Dahl, Tobias and Warzocha, Krzysztof Jedrzejczak, Wieslaw W. Kyrcz-Krzemien, Slawomira Kiani, Alexander Supekar, Sharon Ferreira, AnaRita and Shah, Seema Luis Steegmann, Juan Baccarani, Michele

Published
2019

42. Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients

Author

Palandri, Francesca, Palumbo, Giuseppe A., Bonifacio, Massimiliano, Breccia, Massimo, Latagliata, Roberto, Martino, Bruno, Polverelli, Nicola, Abruzzese, Elisabetta, Tiribelli, Mario, Nicolosi, Maura, Bergamaschi, Micaela, Tieghi, Alessia, Iurlo, Alessandra, Sgherza, Nicola, Cavazzini, Francesco, Isidori, Alessandro, Binotto, Gianni, Ibatici, Adalberto, Crugnola, Monica, Heidel, Florian, Bosi, Costanza, Bartoletti, Daniela, Auteri, Giuseppe, Catani, Lucia, Cuneo, Antonio, Aversa, Franco, Semenzato, Gianpietro, Cavo, Michele, Vianelli, Nicola, and Benevolo, Giulia

Published
2018
Full Text
View/download PDF

44. Bosutinib in the real‐life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine‐kinase inhibitors.

Author

Latagliata, Roberto, Attolico, Immacolata, Trawinska, Malgorzata Monika, Capodanno, Isabella, Annunziata, Mario, Elena, Chiara, Luciano, Luigiana, Crugnola, Monica, Bergamaschi, Micaela, Bonifacio, Massimiliano, Baratè, Claudia, Mauro, Endri, Binotto, Gianni, Sgherza, Nicola, Aguzzi, Chiara, Monteleone, Barbara, Sorà, Federica, Caocci, Giovanni, Luzi, Debora, and Mariggiò, Elena

Subjects
CHRONIC myeloid leukemia, PROTEIN-tyrosine kinase inhibitors, OLDER patients, OVERALL survival, DASATINIB, KINASE inhibitors
Abstract

To evaluate the role of bosutinib in elderly patients aged >65 years with chronic myeloid leukemia (CML), a real‐life cohort of 101 chronic‐phase CML patients followed up in 23 Italian centers and treated with bosutinib in second or a subsequent line was retrospectively evaluated. Starting dose of bosutinib was 500 mg/day in 25 patients (24.8%), 400 mg/day in 7 patients (6.9%), 300 mg/day in 33 patients (32.7%), 200 mg/day in 34 patients (33.6%), and 100 mg/day in 2 patients (2.0%). Grade 3/4 hematological toxicity occurred in 7/101 patients (6.9%) and grade 3/4 extra‐hematological toxicity in 19/101 patients (18.8%). Permanent bosutinib discontinuation due to toxicity was needed in 12 patients (11.9%). Among the 96 patients evaluable for response, 74 (77.0%) achieved a complete cytogenetic response (CCyR), while 64 of these 74 patients in CCyR (66.6% of all 96 evaluable patients) also achieved a molecular response (MR) (major MR [MR 3.0] in 21 [21.8%], deep MR [MR 4.0/4.5] in 43 [44.8%]). The 3‐year event‐free survival and overall survival of the whole patients' cohort from bosutinib start were 60.9% (CI 95% 49.3–72.5) and 86.4% (CI 95% 77.2–95.6), respectively. Our real‐life data show that bosutinib is effective, with a favorable safety profile, also in elderly patients with important comorbidities and resistance and/or intolerance to previous tyrosine‐kinase inhibitor treatments. As a consequence, it could play a significant role in current clinical practice for frail patients. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

45. Impact of comorbidities and body mass index on the outcome of polycythemia vera patients.

Author

Benevolo, Giulia, Elli, Elena M., Bartoletti, Daniela, Latagliata, Roberto, Tiribelli, Mario, Heidel, Florian H., Cavazzini, Francesco, Bonifacio, Massimiliano, Crugnola, Monica, Binotto, Gianni, D'Addio, Alessandra, Tieghi, Alessia, Bergamaschi, Micaela, Caocci, Giovanni, Polverelli, Nicola, Bossi, Elisa, Auteri, Giuseppe, Carmosino, Ida, Catani, Lucia, and Cuneo, Antonio

Subjects
BODY mass index, POLYCYTHEMIA vera, COMORBIDITY, MYELOFIBROSIS, CARDIOVASCULAR diseases risk factors, GOODNESS-of-fit tests
Abstract

In 816 patients with 2016 World Health Organization‐defined polycythemia vera (PV) enrolled in a multicenter retrospective study, we investigated the predictive value of Charlson comorbidity index (CCI) and body mass index (BMI) on thrombosis, progression to post‐PV myelofibrosis (PPV‐MF) and survival. Patients were subgrouped according to CCI = 0 (58.1%, no comorbidities) or CCI ≥ 1 (41.9%) and according to normal/underweight (BMI < 25, 54.5%) or overweight/obesity (BMI ≥ 25, 45.5%) at PV diagnosis. BMI was available for 529 patients. Patients with CCI ≥ 1 were older and more frequently presented cardiovascular risk factors compared to patients with CCI = 0 (p < 0.001), while overweight/obese patients were more frequently males (p < 0.001). Cumulative incidence of thromboses with death as competing risk was 13.3% at 10 years. Multivariable analysis with death as competing risk showed that previous thromboses (subdistribution hazard ratio [SHR]: 2.1, p = 0.01) and hypertension (SHR: 1.77, p = 0.04) were significantly associated with a higher thrombotic risk, while BMI ≥ 25 lost statistical significance (SHR: 1.69, p = 0.05) and CCI ≥ 1 was excluded after evaluation of goodness of fit. After a median follow‐up of 6.1 years, progression to PPV‐MF occurred in 44 patients, and 75 patients died. BMI ≥ 25 was associated with a lower probability of progression to PPV‐MF (SHR: 0.38, CI95%: 0.15–0.94, p = 0.04) and better survival (hazard ratio [HR]: 0.42, CI95%: 0.18–0.97, p = 0.04). CCI ≥ 1 did not affect progression to PPV‐MF (p = 0.44) or survival (p = 0.71). The evaluation of CCI and BMI may improve the prognostic definition of PV. In patients with hypertension an accurate evaluation of thrombotic risk is warranted. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

48. Peripheral Blasts Are Associated with Response to Ruxolitinib and Outcome in Patients with Chronic-Phase Myelofibrosis

Author

Palandri, Francesca, Bartoletti, Daniela, Abruzzese, Elisabetta, Iurlo, Alessandra, Bonifacio, Massimiliano, Caocci, Giovanni, Elli, Elena Maria, Auteri, Giuseppe, Tiribelli, Mario, Polverelli, Nicola, Martino, Bruno, Miglino, Maurizio, Heidel, Florian H., Tieghi, Alessia, Benevolo, Giulia, Beggiato, Eloise, Fava, Carmen, Cavazzini, Francesco, Pugliese, Novella, Binotto, Gianni, Bosi, Costanza, Crugnola, Monica, Ottaviani, Emanuela, Di Pietro, Christian, Micucci, Giorgia, Trawinska, Malgorzata Monika, Cuneo, Antonio, Bocchia, Monica, Krampera, Mauro, Pane, Fabrizio, Lemoli, Roberto M., Cilloni, Daniela, Cavo, Michele, Vianelli, Nicola, Palumbo, Giuseppe A., and Breccia, Massimo

Published
2021
Full Text
View/download PDF

49. Choice of Frontline Tyrosine-Kinase Inhibitor in Very Elderly Patients with Chronic Myeloid Leukemia: A “Campus CML” Study

Author

Latagliata, Roberto, Capodanno, Isabella, Miggiano, Maria Cristina, Bucelli, Cristina, Cavazzini, Francesco, Leonetti Crescenzi, Sabrina, Russo, Sabina, Colafigli, Gioia, Annunziata, Mario, Sora, Federica, Bonifacio, Massimiliano, Luciano, Luigiana, Caocci, Giovanni, Loglisci, Giuseppina, Elena, Chiara, Mullai, Rikard, Attolico, Imma, Binotto, Gianni, Crisà, Elena, Iurlo, Alessandra, Sportoletti, Paolo, Di Veroli, Ambra, Scortechini, Anna Rita, Leporace, Annapaola, Maggi, Alessandro, Crugnola, Monica, Stagno, Fabio, Sancetta, Rosaria, Murgano, Pamela, Rapezzi, Davide, Luzi, Debora, Bocchia, Monica, Fava, Carmen, Malato, Alessandra, Vincelli, Jolanda Donatella, Abruzzese, Elisabetta, Saglio, Giuseppe Nicola, Specchia, Giorgina, Breccia, Massimo, and Tiribelli, Mario

Published
2021
Full Text
View/download PDF

50. Bemcentinib (Oral AXL Inhibitor) in Combination with Low-Dose Cytarabine Is Well Tolerated and Efficacious in Older Relapsed AML Patients.Updates from the Ongoing Phase II Trial (NCT02488408) and Preliminary Translational Results Indicating Bemcentinib Elicits Anti-AML Immune Responses

Author

Loges, Sonja, Sutamtewagul, Grerk, Heuser, Michael, Chromik, Jörg, Kapp-Schwoerer, Silke, Crugnola, Monica, Di Renzo, Nicola, Lemoli, Roberto M., Mattei, Daniele Giovanni, Ben Batalla, Isabel, Hellesøy, Monica, Waizenegger, Jonas, Janning, Melanie, Imbusch, Charles D., Beumer, Niklas, Rayford, Austin, Nautiyal, Jaya, Berkman-Gottlieb, Tzivia, Micklem, David, Gabra, Hani, Gorcea-Carson, Claudia, Lorens, James B., Fiedler, Walter, Alvarado, Yesid, Gjertsen, Bjorn T., and Rieckmann, Lisa-Marie

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results